Physician profile
Roheen Raithatha
NPI 1851558936
$830,455.57
in general payments reported to CMS, 2019-2025
30 companies · $288K in 2025
The $288K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $42K · 2021: $38K · 2022: $94K · 2023: $131K · 2024: $135K · 2025: $288K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $422K · Travel and Lodging: $62K · Consulting Fee: $52K · Food and Beverage: $19K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $421,932.02 |
| Travel and Lodging | $61,630.05 |
| Consulting Fee | $51,992.49 |
| Food and Beverage | $18,595.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $272,465.59 | 2019-2025 | |
| Medtronic, INC. | $143,380.82 | 2020-2025 | Propel, Stealthstation S8 Platform, Sinuva |
| Regeneron Healthcare Solutions, INC. | $128,388.64 | 2019-2025 | Dupixent |
| Optinose US, INC. | $91,939.20 | 2019-2025 | |
| Medtronic USA, INC. | $65,300.13 | 2019-2020 | |
| Aerin Medical INC. | $43,379.19 | 2020-2025 | |
| Intersect Ent, INC. | $39,061.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $29,013.23 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $8,540.93 | 2025 | Tezspire |
| Stryker Corporation | $3,432.99 | 2019-2025 | Scopis Ent, Clarifix Cryotherapy Device, Audion Et Dilation System |
| Regeneron Pharmaceuticals, INC. | $2,478.02 | 2023-2025 | Dupixent |
| Neurent Medical Limited | $1,329.33 | 2022-2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Kaleo, INC. | $436.38 | 2020-2024 | Auvi-Q |
| Spirair, INC. | $294.07 | 2025 | |
| Arrinex, INC. | $237.07 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $185.52 | 2019-2021 | |
| Alk-Abello, INC | $93.98 | 2019-2025 | Grastek, Ragwitek, Odactra |
| Aimmune Therapeutics, INC. | $71.02 | 2022 | |
| Integra Lifesciences Corporation | $58.83 | 2024-2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Smith+Nephew, INC. | $55.53 | 2022-2023 | Coblation, Rapid Rhino, Tula |
| Acclarent, INC | $46.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $40.89 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $39.90 | 2023 | Ryaltris |
| Amgen INC. | $37.61 | 2025 | |
| Phadia US INC. | $34.21 | 2020-2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.95 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.09 | 2022 | |
| Merck Sharp & Dohme LLC | $21.15 | 2023 | |
| Octapharma USA, INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roheen Raithatha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.